Although some studies have shown that patients with PBRM1 loss in ccRCC experience increased clinical benefit from ICIs [12,35], data on the effect of PBRM1 loss regarding immune responsiveness are inconsistent [13,36,37]. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.